Tumor Biology

, Volume 36, Issue 10, pp 7849–7858 | Cite as

CMTM3 inhibits cell growth and migration and predicts favorable survival in oral squamous cell carcinoma

  • Heyu Zhang
  • Jianyun Zhang
  • Xu Nan
  • Xuefen Li
  • Jiafei Qu
  • Yingying Hong
  • Lisha Sun
  • Yan Chen
  • Tiejun Li
Research Article


Downregulation of CKLF-like MARVEL transmembrane domain-containing member 3 (CMTM3) has been reported in a number of human tumors. However, the role of CMTM3 in oral squamous cell carcinoma (OSCC) remains largely unknown. In this study, we showed that the expression of CMTM3 was significantly reduced in OSCC cell lines and primary tumor specimens (P < 0.001). Methylation-specific PCR showed hypermethylation in CMTM3 promoter in a significant proportion of tumor tissues (61 %). The expression of CMTM3 was associated with T stage, lymph node metastasis, tumor node metastasis (TNM) stage, and recurrence of OSCC patients (P < 0.05, n = 201). More importantly, CMTM3 expression was associated with the prognosis of OSCC patients (P < 0.001) and was an independent prognostic factor (hazard ratio = 0.593, 95 % confidence interval, 0.272–1.292; P = 0.039). Overexpression of CMTM3 inhibited the growth and migration of OSCC cells. In vivo experiments also showed that the growth of OSCC xenografts in nude mice was significantly inhibited by CMTM3 overexpression. These findings indicate that downregulation of CMTM3 due to promoter hypermethylation contributed to the proliferation and migration of OSCC cells and suggest that CMTM3 is an independent prognostic factor for the evaluation of the survival of OSCC patients.


CMTM3 Promoter methylation Tumor suppressor gene Oral squamous cell carcinoma 



This work was supported by the National Natural Science Foundation of China (grant numbers 81300894, 81030018, 30901680).

Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Tang WY, Ho SM. Epigenetic reprogramming and imprinting in origins of disease. Rev Endocr Metab Disord. 2007;8:173–82.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Feinberg AP. Cancer epigenetics takes center stage. Proc Natl Acad Sci U S A. 2001;98(2):392–4.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28(10):1057–68.CrossRefPubMedGoogle Scholar
  5. 5.
    Guerrero-Preston R, Michailidi C, Marchionni L, et al. Key tumor suppressor genes inactivated by “greater promoter” methylation and somatic mutations in head and neck cancer. Epigenetics. 2014;9(7):1031–46.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Arantes LM, de Carvalho AC, Melendez ME, et al. Methylation as a biomarker for head and neck cancer. Oral Oncol. 2014;50(6):587–92.CrossRefPubMedGoogle Scholar
  7. 7.
    Khor GH, Froemming GR, Zain RB, et al. DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma. Int J Med Sci. 2013;10(12):1727–39.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Towle R, Truong D, Hogg K, et al. Global analysis of DNA methylation changes during progression of oral cancer. Oral Oncol. 2013;49(11):1033–42.CrossRefPubMedGoogle Scholar
  9. 9.
    Mascolo M, Siano M, Ilardi G, et al. Epigenetic disregulation in oral cancer. Int J Mol Sci. 2012;13(2):2331–53.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Khor GH, Froemming GR, Zain RB, et al. Screening of differential promoter hypermethylated genes in primary oral squamous cell carcinoma. Asian Pac J Cancer Prev. 2014;15(20):8957–61.CrossRefPubMedGoogle Scholar
  11. 11.
    Al-Kaabi A, van Bockel LW, Pothen AJ, et al. p16INK4A and p14ARF gene promoter hypermethylation as prognostic biomarker in oral and oropharyngeal squamous cell carcinoma: a review. Dis Markers. 2014;2014:260549.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zhang S, Feng XL, Shi L, et al. Genome-wide analysis of DNA methylation in tongue squamous cell carcinoma. Oncol Rep. 2013;29(5):1819–26.PubMedGoogle Scholar
  13. 13.
    Zhang W, Mendoza MC, Pei X, et al. Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling. J Biol Chem. 2012;287(15):11850–8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Han W, Ding P, Xu M, et al. Identification of eight genes encoding chemokine-like factor superfamily members 1–8 (CKLFSF1–8) by in silico cloning and experimental validation. Genomics. 2003;81(6):609–17.CrossRefPubMedGoogle Scholar
  15. 15.
    Imamura Y, Katahira T, Kitamura D. Identification and characterization of a novel BASH N terminus-associated protein, BNAS2. J Biol Chem. 2004;279(25):26425–32.CrossRefPubMedGoogle Scholar
  16. 16.
    Wang Y, Li T, Qiu X, et al. CMTM3 can affect the transcription activity of androgen receptor and inhibit the expression level of PSA in LNCaP cells. Biochem Biophys Res Commun. 2008;371(1):54–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Wang Y, Li J, Cui Y, et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 2009;69(12):5194–201.CrossRefPubMedGoogle Scholar
  18. 18.
    Xie J, Yuan Y, Liu Z, et al. CMTM3 is frequently reduced in clear cell renal cell carcinoma and exhibits tumor suppressor activities. Clin Transl Oncol. 2014;16(4):402–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Li Z, Xie J, Wu J, et al. CMTM3 inhibits human testicular cancer cell growth through inducing cell-cycle arrest and apoptosis. PLoS One. 2014;9(2), e88965.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Su Y, Lin Y, Zhang L, et al. CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer. Cancer Sci. 2013;105(1):26–34.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Cakir M, Grossman AB. Targeting MAPK (Ras/ERK) and PI3K/Akt pathways in pituitary tumorigenesis. Expert Opin Ther Targets. 2009;13(9):1121–34.CrossRefPubMedGoogle Scholar
  22. 22.
    Dworakowska D, Wlodek E, Leontiou CA, et al. Activation of RAF/MEK/ERK and PI3K/Akt/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer. 2009;16(4):1329–38.CrossRefPubMedGoogle Scholar
  23. 23.
    Rakha EA, Pinder SE, Paish CE, et al. Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1. Br J Cancer. 2004;91(8):1591–6.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Sun M, Ma L, Xu L, et al. A human novel gene DERPC on 16q22.1 inhibits prostate tumor cell growth and its expression is decreased in prostate and renal tumors. Mol Med. 2002;8(10):655–63.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Fu L, Dong SS, Xie YW, et al. Down-regulation of tyrosine aminotransferase at a frequently deleted region 16q22 contributes to the pathogenesis of hepatocellular carcinoma. Hepatology. 2010;51(5):1624–34.CrossRefPubMedGoogle Scholar
  26. 26.
    Dawson AJ, Bal S, McTavish B, et al. Inversion and deletion of 16q22 defined by array CGH, FISH, and RT-PCR in a patient with AML. Cancer Genet. 2011;204(6):344–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Towle R, Garnis C. Methylation-mediated molecular dysregulation in clinical oral malignancy. J Oncol. 2012;2012:170172.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Shah NG, Trivedi TI, Tankshali RA, et al. Prognostic significance of molecular markers in oral squamous cell carcinoma: a multivariate analysis. Head Neck. 2009;31(12):1544–56.CrossRefPubMedGoogle Scholar
  29. 29.
    Brockmeyer P, Jung K, Perske C, et al. Membrane connexin 43 acts as an independent prognostic marker in oral squamous cell carcinoma. Int J Oncol. 2014;45(1):273–81.PubMedGoogle Scholar
  30. 30.
    Cheng AN, Jiang SS, Fan CC, et al. Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents. Cancer Lett. 2014;337(2):218–25.CrossRefGoogle Scholar
  31. 31.
    Li H, Li J, Su Y, et al. A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth. Oncogene. 2013;33(24):3109–18.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Heyu Zhang
    • 1
  • Jianyun Zhang
    • 2
  • Xu Nan
    • 3
  • Xuefen Li
    • 1
  • Jiafei Qu
    • 2
  • Yingying Hong
    • 2
  • Lisha Sun
    • 1
  • Yan Chen
    • 2
  • Tiejun Li
    • 2
  1. 1.Central LaboratoryPeking University School and Hospital of StomatologyBeijingChina
  2. 2.Department of Oral PathologyPeking University School and Hospital of StomatologyBeijingChina
  3. 3.Center for Human Disease Genomics, School of Basic Medical SciencesPeking UniversityBeijingChina

Personalised recommendations